Analyzing mixture toxicity requires an in-depth understanding of the mechanisms of action of its individual components. Substances with the same target organ, same toxic effect and same mode of action (MoA) are believed to cause additive effects, whereas substances with different MoAs are assumed to act independently. Here, we tested 2 triazole fungicides, propiconazole, and tebuconazole (Te), for individual and combined effects on liver toxicity-related endpoints. Both triazoles are proposed to belong to the same cumulative assessment group and are therefore thought to display similar and additive behavior. Our data show that Te is an antagonist of the constitutive androstane receptor (CAR) in rats and humans, while propiconazole is an agonist of this receptor. Both substances activate the pregnane X-receptor (PXR) and further induce mRNA expression of CYP3A4. CYP3A4 enzyme activity, however, is inhibited by propiconazole. For common targets of PXR and CAR, the activation of PXR by Te overrides CAR inhibition. In summary, propiconazole and Te affect different hepatotoxicity-relevant cellular targets and, depending on the individual endpoint analyzed, act via similar or dissimilar mechanisms. The use of molecular data based on research in human cell systems extends the picture to refine cumulative assessment group grouping and substantially contributes to the understanding of mixture effects of chemicals in biological systems.
To understand the combination effects in a mixture, it is necessary to consider the mode of action (MoA) of the individual substances. Compounds with the same MoA are usually assumed to act additively. Conversely, independent effects are expected for compounds with different MoAs. Hence, understanding and predicting mixture toxicity requires analysis of molecular mechanisms.
Triazole fungicides are a group of widely used pesticides and drugs for which a common MoA with respect to their liver toxicity is assumed. For some azoles (the triazoles epoxiconazole and cyproconazole as well as the imidazole prochloraz), a number of mixture experiments have been conducted in vivo. The results confirm their liver toxicity but only partially dose addition after combined exposure (Heise et al., 2015 (Heise et al., , 2017 Schmidt et al., 2016) .
Two other triazoles, propiconazole (Pi) and tebuconazole (Te), are generally believed to cause hepatic effects in rodents by activation of the constitutive androstane receptor (CAR) (Goetz and Dix, 2009; Tully et al., 2006) . Both substances have been proposed to belong to the same cumulative assessment group (CAG) by the European Food Safety Authority (EFSA) based on the induction of hepatic toxicity (eg, hypertrophy and changes in lipid composition) in rodent animal studies (EFSA, 2012) . Putative CAR-mediated hepatic effects in rodents comprise hepatocyte hypertrophy, a transient proliferative response of hepatocytes connected with an increase in absolute and relative liver weights, as well as the induction of an arsenal of drug-metabolizing enzymes especially from the cytochrome P450 (CYP) families 2B, 2C, and 3A. For a recent review of CAR target gene induction please refer to Kobayashi et al. (2015) . Moreover, CAR activation can modulate proliferation of initiated hepatocytes in a way that cells with mutationally activated Wnt/b-catenin signaling are stimulated to form hepatocellular tumors, whereas the growth of hepatocytes with a mutationally activated mitogenactivated protein kinase signaling pathway is inhibited (Braeuning and Schwarz, 2016) .
However, most foreign compounds are not specific for 1 single xeno-sensing nuclear receptor such as CAR (Tamura et al., 2015) suggested that Te may also act via the nuclear receptors pregnane X-receptor (PXR) and peroxisome proliferatoractivated receptor a and thus exhibits a slightly different MoA than a pure CAR activator (Tamura et al., 2013 (Tamura et al., , 2015 . With respect to mixture toxicity these findings suggest that Te and Pi might not act additively. Consequently, such a scenario would possibly challenge the grouping of the 2 substances into the same CAG.
Furthermore, triazole-induced hepatic effects might exhibit significant species differences : hepatic responses to cyproconazole were remarkably less pronounced in mice with humanized CAR and PXR as compared with wild-type controls, suggesting that the compound was not able to stimulate the receptors from the 2 species to a comparable degree. Species differences between rodents and humans with regard to the hepatic consequences of CAR activation are controversially discussed among toxicologists. This is especially important since tumor findings in animal studies are considered an important aspect of risk assessment (Braeuning, 2014; Braeuning et al., 2015; Braeuning and Schwarz, 2016; Elcombe et al., 2014; Yamada et al., 2015) . For health risk assessment of pesticide active substances and their mixtures, it seems thus appropriate to obtain data from human cellular systems and to additionally investigate potential differences between man and experimental animals.
To address this issue, a series of experiments in liver cell lines of human and rat origin was conducted to analyze the effects of Pi, Te, and their mixtures on hepatic cells. Analyses included receptor binding and nuclear receptor transactivation, as well as the activity of target gene promoters and the expression of marker genes. Results show that, depending on the endpoints chosen, the 2 triazoles exhibit similar or antagonistic behavior. Detailed molecular data thus point towards the need of including a compound's mechanism(s) of action into the considerations for CAG grouping instead of relying only on histopathological data. (Basel, Switzerland) and Bayer AG (Monheim, Germany), respectively. The test substances were diluted in DMSO (dimethylsulfoxide), resulting in a final DMSO concentration of 0.2% in the treatment medium. DMSO concentrations were equal in all treatment groups.
MATERIALS AND METHODS
In silico docking of the CAR ligand-binding domain. Docking studies were carried out using the software MOE (version 2016.0802, CCG, Motreal, Cananda) . The crystal structure of the CAR was prepared using PDB structure 1XV9 B subunit as starting geometry. The reference ligand (pregnane-3, 20-dione) and the water molecules not conserved within the crystal structure were removed. Hydrogen atoms were added to the protein molecule using the protonate 3D algorithm and partial charges were assigned using the AMBER 94 forcefield. Energy minimization was performed to relieve the structure from energy strain (gradient: 0.001 RMS kcal/mol/A 2 ). MOE site finder was used to identify the active site. Dummy atoms were assigned to the alpha centers of the active site and were later used for active site mapping during the docking calculations. The ligand structures were prepared using Builder Tool MOE software (version 1.0). The hydrogen atoms were added, partial charges assigned and energy was minimized using same setup as previously described in Krasulova et al. (2016) . The ligands were subsequently docked using the placement Triangle matcher tool (number of return poses was set to 1000). Rescoring was performed using the London dG scoring function (number of return poses set to 30). The position was refined using an induced fit protocol to give limited flexibility to active site residues. The final scores for the 10 best-scoring poses were calculated by GBVI/WSA dG. Average root mean square deviation for the 10 best-scoring poses after redocking the reference ligand was 0.07 Å .
Fluorescence resonance energy transfer assay. The LanthaScreenTM TR-fluorescence resonance energy transfer (FRET) CAR Coactivator Binding Assay (Thermo Fischer Scientific) was used under the same conditions as was described in our previous work (Carazo and Pavek, 2015) . Briefly, interaction of a ligand with CAR ligand-binding domain (LBD) results in recruitment of PGC1a-fragment and in emission shift from 495 to 520 nm. The 520/495 nm ratio of DMSO (the vehicle sample) was set to 1 and the rest of samples was calculated as manifolds of the control.
Cell culture. HepaRG cells were obtained from Biopredic International (Saint Gr egoire, France) and cultured as previously described in Gripon et al. (2002) . In brief, HepaRG cells were incubated for 2 weeks in the proliferation medium containing Williams E medium (Pan-Biotech GmbH, Aidenbach, Germany), 10% fetal calf serum (FCS; PAN-Biotech GmbH, Aidenbach, Germany), 100 U/ml penicillin, 100 mg/ml streptomycin, 0.05% human insulin (PAA Laboratories GmbH, Pasching, Austria) and 50 mM hydrocortisone-hemisuccinate (Sigma-Aldrich, Taufkirchen, Germany). Afterwards, cells were differentiated for further 2 weeks in differentiation medium, which is made from the proliferation medium by addition of 1.7% DMSO. The treatment of the cells with the triazoles was conducted in phenolred-free Williams E medium (Pan-Biotech GmbH, Aidenbach, Germany), which contained the same supplements as the proliferation medium, but only 2% FCS. HepG2 cells (ECACC, Porton Down, UK) were incubated in DMEM medium (Pan-Biotech GmbH, Aidenbach, Germany) containing 10% FCS. Passaging of the cells was carried out every 3-4 days at a confluence of about 80%. Cells were treated with triazoles in phenol-red-free DMEM medium supplemented with 10% FCS (Pan-Biotech GmbH, Aidenbach, Germany). Both cell lines were incubated at 37 C and 5% CO 2 in a humidified atmosphere in a Binder cell culture incubator.
Isolation of primary rat hepatocytes. Rat hepatocytes were isolated as described previously in Puschel et al. (1993) and Schraplau et al. (2015) . In brief, hepatocytes were isolated from young adult male Wistar rats (Charles River, Sulzfeld, Germany) by collagenase-free perfusion according to (Meredith, 1988) . Cells were subsequently plated in Williams E medium (SigmaAldrich, Deisenhofen, Germany) supplemented with 0.5 nM insulin (Sigma-Aldrich), 100 nM dexamethasone (Sigma-Aldrich), 10 mg/ml penicillin/streptomycin (Biochrom, Berlin, Germany) and for the first 4 h of cultivation 4% newborn calf serum (Biochrom). Cells were further cultivated under serum-free conditions at 37 C and 5% CO 2 in a humidified atmosphere. Data from 3 rats individually perfused at 3 different days were generated to result in 3 independent hepatocyte experiments.
Cytotoxicity testing. Cytotoxicity was analyzed using the colorimetric MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) reduction assay in 96-well format according to standard protocols (Braeuning et al., 2012) . The detergent Triton X-100 (0.01%) served as positive control.
Plasmids, transfection, and luciferase assays. HepG2 cells and primary rat hepatocytes were used for the luciferase assays. In the HepG2 cells 5 different assays (CAR and PXR transactivation assays and CYP2B6 [CAR], CYP2B6 [PXR] , and CYP3A4 promoter assays) were performed. The cells were transfected with 3 plasmids (see Table 1 ). In case of the transactivation assays, the first plasmid is based on a fusion protein of GAL4 with the LBD of the human nuclear receptor and the second plasmid contains the firefly luciferase reporter gene under control of 5 copies of the GAL4 upstream activation sequence (UAS) and of a minimal thymidine kinase promoter. The CAR LBD-encoding plasmid pGAL4/DBD-CAR/LBD(þ3aa) contains 3 additional amino acids, which prevent constitutive activity and spontaneous nuclear localization of the gene product in the absence of activating ligands (Kanno and Inouye, 2010) . For the promoter assays, the luciferase reporter construct is driven by a fragment of the promoter of the human CAR/PXR-responsive CYP2B6/CYP3A4 gene. Cells were cotransfected with an expression vector for the human nuclear receptor (hCAR or hPXR). The third plasmid expresses for all assays the renilla luciferase constitutively and serves as an internal control.
HepG2 cells were transiently transfected using TransIT-LT1 (Mirus Bio LLC, Madison, Wisconsin). After treatment and lysis of the cells (100 mM potassium phosphate with 0.2% (v/v) Triton X-100, pH 7.8), luminescence was measured using a plate reader (Infinite M200PRO, Tecan, M€ annedorf, Switzerland) according to the Dual Luciferase Assay protocol provided by the supplier (Promega, Madison, Wisconsin).
Rat hepatocytes were transiently transfected using a modified calcium phosphate precipitation method as described previously in Schraplau et al. (2015) using 1 mg of pGL3-based plasmids encoding firefly luciferase under the control of a rat Cyp2b1 wild type promoter, or under the control of a mutant version of the rat Cyp2b1 promoter lacking the functional CARbinding sites PBREM (phenobarbital-responsive elements) (Bauer et al., 2004; Wieneke et al., 2007) . Cells were treated with test compounds 24 h after transfection for 48 h. After lysis of the cells (100 mM potassium phosphate with 0.2% (v/v) Triton X-100, pH 7.8), luminescence was measured using a plate reader (Infinite M200PRO).
RNA isolation and real-time RT-PCR. RNA was isolated and realtime RT-PCR performed as described previously in Heise et al. (2015) . RNA was isolated from HepaRG cells or primary rat hepatocytes after treatment of 24 or 48 h, respectively using peqGOLD TriFast (peqlab, Erlangen, Germany). Quality and quantity of the isolated RNA were controlled with a Nanodrop spectrophotometer (NanoDrop 2000, Thermo Fisher Scientific, Waltham, Massachusetts). Reverse transcription of 1 mg RNA was conducted using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany). The quantitative real-time PCR was performed on an ABI 7900HT instrument (Applied Biosystems) using SYBR green mastermix (Thermo Fisher Scientific) and primers (0.25 mM, synthesized at Eurofins Genomics, see Table 2 ).
CYP activity assays. Enzymatic activities of CYP2B6 and CYP3A4 were assessed using a mass-spectrometric approach as previously described in Feidt et al. (2010) . In brief, HepaRG cells were incubated with the test substances as outlined earlier.
Following 24 h of incubation, different CYP substrates (see Table 3 ) were added to the medium. After 2 h of incubation, 100 ml supernatant samples were mixed with 10 ml of 250 mM formic acid and then used for mass-spectrometric quantification as previously described in Feidt et al. (2010) . Inhibition of CYP2B6 and CYP3A4 enzymatic activities by the test substances was monitored with recombinant human CYPs expressed in baculovirus-infected insect cells and luciferase-based detection of substrate conversion by use of commercial assays (Promega). For additional details on the method, please refer to a recent publication (Dusek et al., 2017) .
Statistical analysis. For statistical analysis, SigmaPlot for Windows software (Version 13.0, Systat Software Inc. 2008) was used. Data were first analyzed for normal distribution and for homogeneity of variances by the Shapiro-Wilks and BrownForsythe tests. Based on these test results, nonparametric testing was considered the adequate testing method for the present datasets. The Mann-Whitney rank sum test was used to compare different groups (solvent control and respective treatment group). Statistical significance for the treatment with positive controls was determined separately from test compound treatment. Asterisks (*) define statistical significance if p .05. Error bars depict the standard deviation. For a statistical doseresponse modeling to analyze concentration addition the PROAST software (www.proast.nl) was used as described previously in Kienhuis et al. (2015) .
RESULTS

Pi and Te Are Potential Ligands of Human CAR
To assess the potential of the 2 compounds to activate human CAR, we performed in silico analyses for docking of the substances into the ligand-binding pocket of human CAR (Figure 1) . The resulting values of free binding energy (DG) were calculated for Pi (À8.49 kcal/mol; Figs. 1A and 1B) and Te (À8.20 kcal/mol; Figs. 1C and 1D) . These values suggest a lower affinity of the 2 compounds towards the CAR LBD than pregnane-3, 20-dione (À9.15 kcal/mol), which served as a reference CAR ligand. 3D visualization revealed that both Pi (pink) and Te (yellow) were shown to fit within the active site. Also the reference CAR ligand pregnane-3, 20-dione binds to the same active site (green). Both Pi and Te docked with their triazole moiety oriented towards the active site. Similarly, the oxo-group in position 3 of pregnane-3, 20-dione is also directed towards the active site. Such binding features suggest that both drugs have considerable affinities towards the CAR LBD despite their lower calculated free binding energy, as compared with the reference compound.
In a next step, the interaction of both compounds with the recombinant LBD of human CAR was assessed using the Lantha-Screen TR-FRET approach. As shown in Figure 1E , weak signals of CAR binding were detected for both, Pi as well as Te. These effects, however, were considerably lower than for 6-(4-
, a model experimental activator of human CAR. The lack of clear-cut dose-response curves might be related to beginning denaturation of the assay proteins at higher compound concentrations. Interestingly, we observed an inverse concentration-dependent effect for Te potentially suggesting CAR antagonism at the 30 mM concentration of Te ( Figure 1E ).
Pi and Te Have Opposing Effects on the Activity of Human CAR
The ability of Pi and Te to activate human CAR was tested in different luciferase reporter gene systems. To exclude artifacts caused by cytotoxic concentrations of the test compounds, we first tested cytotoxicity using the MTT cell viability assay (Supplementary Figure 1) . Only nontoxic concentrations of Pi and Te up to 20 or 40 mM were applied in subsequent experiments. As a first step of reporter gene analysis, a reporter system based on a GAL4 fusion construct with the LBD of human CAR was used in human HepG2 hepatoma cells. This reporter system was activated by the model CAR activator and direct ligand CITCO, but not by the indirect CAR activator phenobarbital. This indicates that the system is well-suited to depict the direct action of CAR ligands at the CAR LBD (Supplementary Figure 2) . We observed a considerable and statistically significant dose-dependent activation of CARdependent reporter activity by Pi, which suggests that Pi acts as a direct CAR activator (Figure 2A) . At the highest concentration tested (40 mM), Pi induced the reporter system approximately 4-fold, which was considerably lower than the >100-fold induction by CITCO, thus indicating that Pi is a rather weak direct agonist of CAR. Te also acted on CAR, but in contrast to Pi, a dose-dependent and statistically significant inhibition of CARdependent reporter activity by Te was recorded ( Figure 2B ). Inhibition by 40 mM Te, the highest concentration tested, suppressed basal reporter activities by approximately 70%. The effects exerted on the CAR reporter by Pi and Te antagonized each other when applied to the cells in different mixtures ( Figure 2C ). Likewise, CAR activation by the model agonist CITCO was dose-dependently counteracted by co-incubation with Te when the latter compound was applied in concentrations > 10 mM ( Figure 2D ). To verify the results of the GAL4-based reporter assay, we additionally used a more physiological luciferase reporter system based on a fragment of the CAR-responsive human CYP2B6 gene promoter. HepG2 cells normally are deficient in their expression of several important xenobiotic receptors including CAR and PXR. For the herein presented experiments, the CYP2B6 gene promoter was therefore simultaneously cotransfected with an expression vector for human CAR to ensure functionality of that signaling pathway. This was confirmed by an approximately 30-fold induction of the reporter by the CAR activator CITCO, whereas the model PXR activator SR12813 did not exert any effect. As expected, Pi treatment of HepG2 cells significantly induced CYP2B6 promoter-driven reporter activities up to approximately 6-fold in a concentration-dependent manner, while Te was not effective and rather displayed a tendency for inhibition of the reporter system ( Figure 3A ). This was similarly monitored up to the highest possible non-cytotoxic concentration of the compound (80 mM; data not shown). Similarly, an up to 5-fold induction by Pi was seen when using a luciferase reporter system based on the CAR-responsive rat Cyp2b1 promoter in primary rat hepatocytes ( Figure 3B ). In contrast, Te did not substantially affect Cyp2b1 promoter-dependent reporter activities ( Figure 3B ). In addition, a modified version of the rat Cyp2b1 promoter-driven luciferase reporter system was employed, which does not possess functional binding sites for CAR (PBREM). Results obtained with this plasmid in primary rat hepatocytes showed a significantly decreased responsiveness to Pi at all concentrations tested, indicating that a major part of Cyp2b1 promoter activation by Pi was mediated by CAR ( Figure 3B ). As with the wild type construct, Te did not activate the CAR-binding site-deficient version of the Cyp2b1 promoterdriven luciferase reporter construct ( Figure 3B ).
Taken together, the previous results indicated that Pi is an agonist of both human and rat CAR, whereas Te acts as an antagonist of the receptors. Further verification of the data was performed at the mRNA and enzyme activity levels. Differentiated HepaRG human hepatoma cells were selected for these analyses due to the fact that this cell line provides high expression of CAR target genes related to drug metabolism, together with functional physiological regulation of CARdependent gene expression. To this end, we analyzed the expression of endogenous CYP2B6 in HepaRG cells as a model CAR target gene by quantitative real-time RT-PCR. Figure 4A demonstrates that CYP2B6 mRNA levels were increased in HepaRG cells upon incubation with Pi up to almost 4-fold with statistical significance. Te also led to dose-dependent, increased CYP2B6 mRNA levels, but with a maximum induction of approximately 2.5-fold. At the highest concentration (20 mM) the compound appeared less powerful than Pi ( Figure 4A ). This behavior was unexpected given the previous findings at the reporter gene level (Figure 2) . However, the observation was consistent with the induction of expression of endogenous Cyp2b1 mRNA in primary rat hepatocytes, where a dose-dependent and statistically significant increase was observed for Pi and Te, again with Pi exerting more pronounced effects ( Figure 4B ). In addition, catalytic activity of the CYP2B6 enzyme was measured by mass-spectrometric analyses of hydroxylation of the CYP2B6 substrate bupropione. Figure 4C shows that CYP2B6 activity was increased by Te, which is in accordance with the data on mRNA expression ( Figure 4A) . Surprisingly, an unexpected dose-dependent inhibition of CYP2B6 enzyme activity by Pi was observed ( Figure 4C ). This was due to a strong inhibition of the enzyme by the antifungal compound Pi, which was originally designed to inhibit fungal CYP enzymes (Supplementary Figure  3A) . Te inhibited CYP2B6 only moderately at higher concentrations, which is in line with the minor decrease of cellular Te-induced CYP2B6 activities at higher concentrations of the compound ( Figure 4C; Supplementary Figure 3A) . DMSO itself did not impact on CYP2B6 activities at a concentration of 0.2% (Supplementary Figure 3A) .
Pi and Te Are Activators of PXR
Weak induction of the CAR-binding site-deficient Cyp2b1 promoter reporter assay by the CAR activator Pi, as well as the unexpected increase in CYP2B6 mRNA levels and enzyme activity by the CAR antagonist Te suggested that the mechanism by which these compounds influence xenobiotic metabolism is not restricted to their interference with CAR. We therefore analyzed whether an activation of the receptor PXR might contribute to the observed phenomena. Specifically, HepG2 cells were transfected with the human CYP2B6 promoter-driven luciferase reporter construct. The construct is similar to that one mentioned earlier, but instead of CAR, an expression vector for human PXR was co-transfected, in order to measure PXR-dependency and not CAR-dependent responses of the promoter. Under these porter system, whereas no effect was seen with Te. Response of the reporter system to the model CAR agonist CITCO and the lack of response to the PXR agonist SR12813 are shown for comparison. B, Effects of Pi and Te on rat Cyp2b1 promoter-driven luciferase reporter constructs in primary rat hepatocytes. A CAR-responsive wild type construct or a mutant version of the promoter lacking the functional CAR-binding sites (PBREM) was transfected. The Pi-induced activation of the wild type Cyp2b1 reporter was substantially attenuated when using the nonCAR-responsive mutant. Te treatment did not exert remarkable effects. Mean 6 SD (n ¼ 3 independent experiments, each in 3 replicates) is depicted. Statistical significance (p < .05) is indicated by asterisks.
conditions, the PXR activator and positive control SR12813 were able to stimulate the reporter system by approximately 8-fold ( Figure 5A) . A dose-dependent and statistically significant increase in luciferase activities was observed for both, Pi and Te ( Figure 5A ). Both compounds appeared to have similar potency with regard to PXR-dependent CYP2B6 reporter induction and, accordingly, equimolar mixtures of both substances yielded results, which were in line with the assumption of dose or concentration addition ( Figure 5A; Supplementary Figure 4A) . A similar picture emerged when a luciferase reporter construct driven by the promoter of the human CYP3A4 gene, a model PXR target gene, was used in HepG2 cells, again in combination with cotransfection of an expression vector for PXR ( Figure 5B ; Supplementary Figure 4B) . Additional experiments with a luciferase reporter system activated by a fusion protein of the LBD of PXR and GAL4 confirmed that Pi and Te both effectively activate PXR, by demonstrating a dose-dependent and statistically significant induction of reporter signals ( Figure 5C ). Again, the effects of both compounds appeared comparable in strength and exhibited dose/concentration additive behavior with respect to PXR reporter activation ( Figure 5C ; Supplementary Figure 4C ). This was also observed with respect to endogenous CYP3A4 mRNA expression ( Figure 5D ; Supplementary Figure  4D ). When monitoring CYP3A4 enzyme activities, Pi inhibited the conversion of the model CYP3A4 substrate midazolam ( Figure 5E ), thereby acting similar as previously observed for CYP2B6 ( Figure 4C ). This was caused by substantial direct inhibition of CYP3A4 enzymatic activity by Pi (Supplementary Figure  3B) . Te-treated cells displayed elevated CYP3A4 activities in HepaRG cells, with a tendency for a reduction of activity at higher Te concentrations. The observed induction is in line with the observations at the gene promoter and mRNA levels ( Figure 5E ), and diminished activities at higher Te concentrations reflect the potential of Te to directly inhibit enzymatic activity of CYP3A4 (Supplementary Figure 3B) . DMSO at 0.2% moderately inhibited CYP3A4 activity (Supplementary Figure  3B) . Effects observed with increasing Pi or Te concentrations, however, cannot be attributed to DMSO, due to the fact that the concentrations of the solvent were equal in all treated samples.
DISCUSSION
In this work, we demonstrate that the 2 structurally similar triazole fungicides Pi and Te exert opposite effects on human CAR, with Pi acting agonistic and Te acting antagonistic at the receptor. Pronounced effects were generally observed at concentrations, which can be regarded as supra-physiological with respect to the plasma levels resulting in humans by dietary exposure to residues of triazole-containing plant protection products. Thus, one should not directly conclude from these data that massive CAR activation is expected to occur in the normal human population exposed to small amounts of the compounds. However, this study was conducted to elucidate the MoA of the 2 substances and was not aimed for quantitative risk assessment. Comparisons with the effects caused by model agonists demonstrate that Pi and Te are rather weak to moderate agonists of the 2 receptors. Although in general many drugs and xenobiotics are activators of both, CAR and PXR, compounds eliciting opposite effects on the 2 receptors appear to be rare. There is only 1 report available from the literature in which a number of structurally related dibenzazepine carbamate-based CAR inhibitors have been shown to activate human PXR (Jeske et al., 2017) , thus sharing these characteristics with Te.
Furthermore, present data show that both compounds similarly activate human PXR. This is in line with a previous report on human PXR activation by Pi (Lemaire et al., 2006) . Due to the fact that important target genes such as CYP2B6 and CYP3A4 are shared by the 2 receptors, activation of PXR sufficiently explains the similar gene expression profiles observed in human liver cells despite the differences in CAR activation. For some compounds from the triazole family, simultaneous activation of different nuclear receptors has been shown previously (Goetz and Dix, 2009; Heise et al., 2015 Heise et al., , 2017 . As a general mechanism, the compounds are assumed to exert hepatic effects via CAR in mice (Oshida et al., 2015; Tamura et al., 2015) , and comparable conclusions with regard to CAR activation can be drawn from the induction of characteristic target genes in human cells (Nagai et al., 2016) . However, Tamura et al. (2015) reported that hepatocellular hypertrophy was not solely mediated by CAR, because in contrast to other triazoles this effect was also occurring in CAR knockout mice treated with Te. Additionally, there is accumulating evidence that at least some triazoles target more than 1 xeno-sensing nuclear receptor: Itraconazole has been described as a combined agonist of human PXR and AHR (aryl hydrocarbon receptor) and an inhibitor of human CAR (Omiecinski et al., 2011; Stepankova et al., 2017) . Cyproconazole has been discussed to act via CAR and PXR in mice (Tamura et al., 2015) and the structurally related azole prochloraz has been reported to activate at least CAR and AhR (Heise et al., 2015 (Heise et al., , 2017 Rieke et al., 2014) . Activation of CAR by Pi has been suggested based on gene reporter and transcriptomic data (Currie et al., 2014) , which has been substantiated by our data. In addition, Pi is capable of activating the murine (Ghisari et al., 2015) AHR. PXR activation by Te in human cells has been shown in this study, resembling the findings in mice (Ghisari et al., 2015) . In contrast, activating effects of Te on CAR, as observed by Ghisari et al. (2015) , appear to be a specific observation in mice, since our present analyses in cells of human and rat origin clearly show that Te is an antagonist of CAR in these 2 species. These observations of species specificity of CAR agonism are in line with previous observations on species specificity of other CAR ligands: eg, 1, 4-bis-[2-(3, 5-dichloropyridyloxy)]benzene is a specific agonist at rodent but not human CAR (Soldatow et al., 2016) . Another interesting example of species-specific activity of a drug, which acts differently on human and mouse CAR is the antiemetic meclizine. This compound has agonistic properties at mouse CAR and human PXR, while conflicting data have been reported about its action as an inverse agonist of human CAR (Huang et al., 2004; Lau et al., 2011) . This observation is comparable to what has been observed with Te in our study.
Taken together, the abovementioned findings underline the importance of research with human cells to draw proper conclusions for the activity of test compounds at human nuclear receptors. Moreover, the promiscuity of triazole fungicides with regard to nuclear receptor activation hampers the identification of a single causative toxicological MoA. With regard to this point, it might be interesting to consider in silico structure activity relationship calculations for predicting receptor-interacting properties of such compounds. As evidenced by the data in this article, up-to-date in silico docking models are suited to generally predict interactions with certain receptors. The validity of our molecular docking analyses is underlined by unpublished findings from others also suggesting that Pi and Te are binders of human CAR (I. Eberini, personal communication of unpublished data). However, it is still challenging to predict agonistic or antagonistic behavior based on these computational methods and the similarities of chemical structures. This is underlined by the fact that the rather closely related molecules Pi and Te exerted opposite effects on the receptor CAR. Therefore, experimental determination of receptor agonism or antagonism by methods of molecular biology will still be needed in the near future for providing conclusive answers to these questions.
Some triazoles induce hepatic steatosis in rodents, eg, see (Goetz and Dix, 2009; Heise et al., 2015) . The adverse outcome pathway for steatosis (available at www.aopwiki.org) contains a multitude of possible molecular initiating events, including activation of the nuclear receptors CAR, PXR, and AHR, all of which might be activated by certain members of the triazole fungicide group. Thus, careful dissection of these parallel nuclear receptor-triggered pathways to steatosis will be mandatory in order to obtain meaningful information on details of the toxicological mechanism of an individual compound. This information is particularly relevant for assessing the consequences of exposure to mixtures of these chemicals, as target activation according to the principle of dose or concentration addition can be assumed for compounds with similar MoAs whereas the latter assumption might not be correct in some cases of dissimilar MoAs (eg, Kortenkamp et al., 2009) .
A consequence of continued CAR activation frequently observed in rodent studies is the development of hepatocellular tumors, which is driven by a rodent CAR-dependent, nongenotoxic mechanism termed "phenobarbital-like" (Elcombe et al., 2014) . Human relevance of CAR-mediated tumor promotion is subject to a controversial scientific debate, which is mostly centered on the question whether CAR activation in human cells will exert the same tumor-relevant molecular effects as in rodent cells (see also "Introduction" section). The present data are suited to add another layer of complexity to this topic: Te induces liver tumors in mice when administered at high doses, while no similar increased incidence of liver tumors has been reported for rats (EFSA, 2012) . In a recent publication by Tamura and colleagues, the tumor-promoting effects of Te were characterized using a mouse tumor initiation-promotion model with N-nitrosodiethylamine as initiator, followed by long-term treatment with Te (Tamura et al., 2015) . The resulting altered hepatocellular foci were mainly eosinophilic (Tamura et al., 2015) , which is characteristic for phenobarbital-promoted liver tumors (Lee, 2000) . These foci disappeared when a CAR knockout mouse model was used (Tamura et al., 2015) . These data strongly suggest that CAR plays an important role in Te-induced liver tumorigenesis in mice. This would be in line with the findings on mouse CAR by (Ghisari et al., 2015) and not in contrast to our findings. When discussing the human relevance of these findings one has to consider the observation of species specificity of CAR activation by Te, which might lead to the conclusion that most likely Te-induced mouse tumors are probably not relevant for humans. This is not due to the fact that CAR activators are generally unsuspicious of being carcinogenic to humans, but simply due to the fact that human CAR is not activated by this particular compound. It should be noted that such a conclusion on Te cannot be extended to other compounds, which have the ability to activate human CAR. Deliberate analysis of the molecular MoAs of an individual compounds is needed on a caseby-case basis to fully understand the toxicological properties of foreign compounds and to address potential mixture effects.
In our analyses, Pi and Te act in a concentration-additive manner on drug metabolism-related gene expression at the mRNA level. On the other hand, they have antagonistic effects on CAR. Furthermore, CYP3A4 enzyme activity, which is an important parameter for the metabolism of a variety of drugs and xenobiotics, is induced by Te but repressed by Pi, most likely due to direct enzyme inhibition by Pi. Thus, depending on the endpoint analyzed, mixture effects of Pi and Te might become visible as a form of agonism/activation or as antagonism.
Grouping of substances into CAGs is an important step to reduce the complexity of risk assessment, especially in the field of mixture toxicity (eg, EFSA, 2009) . Nonetheless, the placement of substances into CAGs based on rather crude histopathological effects in animal studies might fall short of the complexity of real life, due to the fact that compounds might act through multiple mechanisms of action and also due to the fact that species differences might exist with regard to the efficacy of foreign compounds to trigger molecular initiating events such as CAR activation. As previously shown for other azoles and the organophosphate chlorpyrifos (Rieke et al., 2014) , the question if substances behave in an additive manner or differently depends also on the endpoint under investigation rather than on the chemical structure or results of histopathology alone. Thus it appears desirable to further pursue the refinement of CAG grouping by using molecular data to assign substances to higher CAG levels, as eg, put forward for pesticidal active substances by the European Food Safety Agency (EFSA, 2012) .
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